+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anal Cancer - Pipeline Review, H2 2019

  • ID: 4861716
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 475 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Antiva Biosciences Inc
  • BNOAT Oncology Inc
  • Eli Lilly and Co
  • IMV Inc
  • Merck & Co Inc
  • PDS Biotechnology Corp
  • MORE
Anal Cancer - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2019, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 17, 13, 1 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Antiva Biosciences Inc
  • BNOAT Oncology Inc
  • Eli Lilly and Co
  • IMV Inc
  • Merck & Co Inc
  • PDS Biotechnology Corp
  • MORE
Introduction
Anal Cancer - Overview
Anal Cancer - Therapeutics Development
Anal Cancer - Therapeutics Assessment
Anal Cancer - Companies Involved in Therapeutics Development
Anal Cancer - Drug Profiles
Anal Cancer - Dormant Projects
Anal Cancer - Discontinued Products
Anal Cancer - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Anal Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Anal Cancer - Pipeline by Antiva Biosciences Inc, H2 2019
Anal Cancer - Pipeline by AstraZeneca Plc, H2 2019
Anal Cancer - Pipeline by Bayer AG, H2 2019
Anal Cancer - Pipeline by BeiGene Ltd, H2 2019
Anal Cancer - Pipeline by Biomimetix JV LLC, H2 2019
Anal Cancer - Pipeline by BNOAT Oncology Inc, H2 2019
Anal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
Anal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2019
Anal Cancer - Pipeline by Cue Biopharma Inc, H2 2019
Anal Cancer - Pipeline by CytomX Therapeutics Inc, H2 2019
Anal Cancer - Pipeline by Eli Lilly and Co, H2 2019
Anal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Anal Cancer - Pipeline by Fujifilm Holdings Corp, H2 2019
Anal Cancer - Pipeline by Genentech Inc, H2 2019
Anal Cancer - Pipeline by Hookipa Pharma Inc, H2 2019
Anal Cancer - Pipeline by IMV Inc, H2 2019
Anal Cancer - Pipeline by Incyte Corp, H2 2019
Anal Cancer - Pipeline by Invectys SA, H2 2019
Anal Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2019
Anal Cancer - Pipeline by Kite Pharma Inc, H2 2019
Anal Cancer - Pipeline by Merck & Co Inc, H2 2019
Anal Cancer - Pipeline by Merck KGaA, H2 2019
Anal Cancer - Pipeline by Molecular Partners AG, H2 2019
Anal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2019
Anal Cancer - Pipeline by Onconova Therapeutics Inc, H2 2019
Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Anal Cancer - Pipeline by PDS Biotechnology Corp, H2 2019
Anal Cancer - Pipeline by Privo Technologies Inc, H2 2019
Anal Cancer - Pipeline by Sierra Oncology Inc, H2 2019
Anal Cancer - Pipeline by SQZ Biotechnologies Co, H2 2019
Anal Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2019
Anal Cancer - Pipeline by Transgene SA, H2 2019
Anal Cancer - Pipeline by Turnstone Biologics Inc, H2 2019
Anal Cancer - Pipeline by Virion Therapeutics LLC, H2 2019
Anal Cancer - Pipeline by Xencor Inc, H2 2019
Anal Cancer - Dormant Projects, H2 2019
Anal Cancer - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Anal Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Antiva Biosciences Inc
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd
  • Biomimetix JV LLC
  • BNOAT Oncology Inc
  • Bristol-Myers Squibb Co
  • Cleveland BioLabs Inc
  • Cue Biopharma Inc
  • CytomX Therapeutics Inc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corp
  • Genentech Inc
  • Hookipa Pharma Inc
  • IMV Inc
  • Incyte Corp
  • Invectys SA
  • ISA Pharmaceuticals BV
  • Kite Pharma Inc
  • Merck & Co Inc
  • Merck KGaA
  • Molecular Partners AG
  • OncoMed Pharmaceuticals Inc
  • Onconova Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • PDS Biotechnology Corp
  • Privo Technologies Inc
  • Sierra Oncology Inc
  • SQZ Biotechnologies Co
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Turnstone Biologics Inc
  • Virion Therapeutics LLC
  • Xencor Inc
Note: Product cover images may vary from those shown
Adroll
adroll